Ibrutinib may be a breakthrough for treatment of a rare lymphoma
Interim results confirmed the “unprecedented” single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.
Diagnosis & Disease Information
DNA-repair problems destroy hardy leukemia cells
Leukemia stem cells that overcome drug therapy can be thwarted when deprived of RAD52, a protein key to DNA repair of these cancer cells.
Oral therapy: Managing side effects can aid adherence
Diligent patient education that addresses adherence and persistence issues can optimize outcomes in patients with gastrointestinal stromal tumors.
Annual report highlights 2012 cancer advances
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year’s most significant developments in cancer.
Optimal dose of dasatinib determined for advanced, recurrent ovarian cancer
A phase I trial determined that dasatinib 150 mg daily is the optimum dose when dasatinib is combined with paclitaxel and carboplatin to treat patients with advanced or recurrent ovarian cancer.
The role of sunitinib in the treatment of GIST
What is the role of sunitinib malate in the treatment of sarcomas?
- Loading...
Loading...
Loading... 
Loading...